Chemotherapy combined with or without targeted therapy is the fundamental treatment for
metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs …

Nearly one-fifth of patients with non-small cell Lung Cancer (NSCLC) will develop liver
metastases (LMs), and the overall treatment strategy of LMs will directly affect the survival of …

Abstract Background Mutations in STK11/LKB1 gene present a negative impact on tumour
immune microenvironment, especially with concomitant activating KRAS mutation. These …

Background Mutations in STK11 (STK11 m) and frequently co-occurring KRAS mutations
(KRAS m/STK11 m) are associated with poor survival in metastatic NSCLC (mNSCLC) …

The composition and relative abundances of immune cells in the tumor microenvironment
are key factors affecting the progression of lung adenocarcinomas (LUADs) and the efficacy …

Abstract Serine Threonine Kinase 11 (STK11) loss of function (LoF) correlates with anti-PD-
1 therapy resistance in patients with KRAS-driven lung adenocarcinoma (LUAD). The …

The last decade has witnessed unprecedented succusses with the use of immune
checkpoint inhibitors in treating cancer. Nevertheless, the proportion of patients who …

The abnormality of surfactant protein C (SFTPC) has been linked to the development of a
number of interstitial lung diseases, according to mounting evidence. Nonetheless, the …

Background Predictive biomarkers in use for immunotherapy in advanced non-small cell
lung cancer are of limited sensitivity and specificity. We analysed the potential of activating …

Opinion Statement The quest for immunotherapy (IT) biomarkers is an element of highest
clinical interest in both solid and hematologic tumors. In non-small-cell lung cancer (NSCLC) …